Tag: Cancer drug

First approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL), the medication known as **bexarotene** is a member of the retinoid drug family. However, it is a distinct subclass of retinoids, often called rexinoids, because it selectively targets retinoid X receptors (RXRs) rather than retinoic acid receptors (RARs).

In December 1992, the U.S. Food and Drug Administration (FDA) first granted approval for the brand-name drug Taxol (paclitaxel) for the treatment of refractory ovarian cancer. The medication's journey from a rare tree bark to a life-saving chemotherapy, however, began decades earlier, marked by scientific breakthroughs, supply challenges, and significant milestones.